9 / 99
H
ADDAD
LA
ET
A
L
.
96
r
Ev
a
SSoC
m
ED
B
raS
2014; 60(2):94-96
cm as the irst-line therapy; and LAM patients with mo-
derate to severe lung disease or rapid progression.
2,3
The-
re are certainly other situations where speciic clinical as-
pects of SEGA, angiomyolipoma or LAM patients may
confer high surgical risks. Therefore, the risks of both,
novel or more conventional therapeutic alternatives should
be discussed with the family before making a decision.
Acknowledgements:
LAH is grateful to Steve Ro-
berds and Katie Smith (Tuberous Sclerosis Alliance, Sil-
ver Spring, MD) for discussion and advices on TSC infor-
mation outreach.
R
EFERENCES
1. Northrup H, Krueger DA, on behalf of the International Tuberous Sclerosis
Complex Consensus Group. Tuberous Sclerosis Complex Diagnostic Criteria
Update: Recommendations of the 2012 International Tuberous Sclerosis
Complex Consensus Conference.
Pediatr Neurol
2013; 49: 243-254.
2. Krueger DA, Northrup H, on behalf of the International Tuberous Sclerosis
Complex Consensus Group. Tuberous Sclerosis Complex Surveillance and
Management: Recommendations of the 2012 International Tuberous
Sclerosis Complex Consensus Conference.
Pediatr Neurol
2013; 49:255-265.
3. Roth J, Roach ES, Bartels U, Jó
ź
wiak S, Koenig MK, Weiner HL, Franz DN,
Wang HZ. Subependymal giant cell astrocytoma: diagnosis, screening, and
treatment. Recommendations from the international tuberous sclerosis
complex consensus conference 2012. Pediatr Neurol. 2013; 49:439-44.
SCIELO BOOK.indb 96
4/22/14 4:35 PM